Full-Time

Head of Analytical Development and Quality Control

Confirmed live in the last 24 hours

Metagenomi

Metagenomi

201-500 employees

Develops genome editing tools for therapeutics

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$220k - $320kAnnually

+ Equity + Bonus

Expert

Oakland, CA, USA

Position located at the Emeryville, California headquarters.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in Biochemistry, Analytical Chemistry, Microbiology, Genetics, or a related life sciences discipline.
  • At least 15 years of experience in analytical development and quality control within the biotech industry.
  • Industry experience managing scientific teams with a proven ability to lead and grow strong technical teams.
  • Extensive industry experience with nucleic acids, viral vectors, lipid nanoparticles, and complex biologicals.
  • Demonstrated expertise in cGMP regulations, ICH guidelines, and USP standards, and their application in clinical development and commercialization.
Responsibilities
  • Establish and lead the ASQC strategy, including tactics, timelines, budgets, and resource allocation.
  • Build and mentor high-performing teams, proactively identify and resolve critical analytical issues, and support talent development and engagement.
  • Develop and qualify phase-appropriate methods for release, characterization, and stability of complex biologicals, utilizing state-of-the-art technologies and approaches.
  • Oversee the qualification, transfer, and execution of analytical and bioanalytical assays, ensuring compliance with cGMP regulations and ICH guidelines.
  • Provide strategic oversight for the design, establishment, and execution of processes and procedures for the lifecycle management of analytical methods for clinical and commercial product testing.
  • Drive the strategy for product quality assessment, analytical comparability, and characterization.
  • Author and review relevant CMC sections of regulatory submissions, serving as an analytical subject matter expert in regulatory interactions.
  • Draft guidelines and set release and stability specifications for clinical-stage and commercial programs.
  • Partner with internal and external stakeholders to lead Quality Target Product Profile and product characterization strategy, enhancing process-to-product understanding and supporting process development and characterization.

Metagenomi focuses on developing new genome editing tools for genetic medicine. The company explores natural environments to find undiscovered genetic material, which is then sequenced and engineered into potential therapeutics. By utilizing artificial intelligence and high-throughput screening, Metagenomi can quickly analyze billions of proteins to identify effective genome editing tools. This approach sets them apart from competitors who may rely on more traditional methods of discovery. The goal of Metagenomi is to create curative treatments for diseases through advanced gene editing techniques, ultimately benefiting healthcare providers and patients.

Company Stage

IPO

Total Funding

$366.1M

Headquarters

Emeryville, California

Founded

2016

Growth & Insights
Headcount

6 month growth

-6%

1 year growth

-6%

2 year growth

51%
Simplify Jobs

Simplify's Take

What believers are saying

  • Rising demand for precision medicine boosts interest in Metagenomi's specific gene editing tools.
  • Advancements in high-throughput screening enhance Metagenomi's therapeutic candidate identification process.
  • Shift towards in-house manufacturing aligns with Metagenomi's strategy to expand its capabilities.

What critics are saying

  • Class action lawsuits could lead to financial liabilities and damage investor confidence.
  • Termination of Moderna partnership may impact Metagenomi's financial projections and strategic plans.
  • Lack of clinical-stage candidates may hinder Metagenomi's ability to attract further investment.

What makes Metagenomi unique

  • Metagenomi uses metagenomics to discover novel genome editing systems for therapeutics.
  • The company leverages AI and high-throughput screening for rapid discovery of gene tools.
  • Metagenomi's gene editing systems are ultra-small, efficient, and have reduced immune response risk.

Help us improve and share your feedback! Did you find this helpful?